---
document_datetime: 2025-09-26 10:38:02
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/eylea-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: eylea-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.5730439
conversion_datetime: 2025-12-28 02:21:48.960712
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Eylea

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                         | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|-----------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IB /  | B.II.f.1.b Extension of the shelf life of the | 25/09/2025                          |                                             | SmPC                             |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000295095                     | finished product - B.II.f.1.b.1 As packaged for sale (supported by real time data) - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |            |            |             |                                                                                                                                                             |
|---------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type II / EMA/VR/0000249440 | C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.4 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data - Accepted Update of sections 4.2, 4.8 and 5.1 of the SmPC in order to update the posology recommendations for indications nAMD and DME and update clinical information based on the final week 156 results from studies PULSAR and PHOTON. PULSAR (20968) was a pivotal Phase 3 study to investigate the efficacy and safety of high dose aflibercept in patients with neovascular age-related macular degeneration (nAMD). PHOTON (21091) was a pivotal Phase 2/3 study to investigate the efficacy and safety of high dose aflibercept in patients with Diabetic Macular Edema (DME). The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to introduce a minor editorial change to the PI. | 22/05/2025 | 25/06/2025 | SmPC and PL | C.I.4 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data |
| Variation type II / EMA/VR/0000248781 | B.I.a.1 Change in the manufacturer of a starting material/reagent/intermediate used                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 25/04/2025 | N/A        |             |                                                                                                                                                             |

<div style=\"page-break-after: always\"></div>

| in the manufacturing process of the active substance or change in the manufacturer (including where relevant quality control testing sites) of the active substance, where no Ph. Eur. Certificate of Suitability is part of the approved dossier - B.I.a.1.e The change relates to a biological active substance or a starting material/reagent/intermediate used in the manufacture of a biological/immunological product - Accepted   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|